• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

    3.750 +0.020 (+0.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 152,466
    Open 3.780
    Bid (Size) 3.700 (100)
    Ask (Size) 3.830 (200)
    Prev. Close 3.730
    Today's Range 3.710 - 4.010
    52wk Range 1.300 - 4.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer ↗
    Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst... 
    Via MarketBeat
    News headline image
    Adagene to Participate in Two Upcoming Investor Conferences
    From Adagene Inc.
    Via GlobeNewswire

    Performance

    YTD
    +103.8%
    +103.8%
    1 Month
    -21.5%
    -21.5%
    3 Month
    -1.8%
    -1.8%
    6 Month
    +36.4%
    +36.4%
    1 Year
    +88.4%
    +88.4%

    More News

    Read More
    News headline image
    Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
    From Adagene Inc.
    Via GlobeNewswire
    Top movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Adagene to Participate in Two Upcoming Investor Conferences
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Provides Business Update and 2026 Objectives
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Participate in Two Investor Conferences in September
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
    Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
    What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
    Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
    The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
    What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
    The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 3.750
    When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
    The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 07/31/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.